Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

41. VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B

VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B Haute Autorité de Santé - VAXELIS, vaccin hexavalent contre diphtérie, tétanos, poliomyélite, coqueluche, infections à Haemophilus influenzae type b, hépatite B Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les (...) Médicaments VAXELIS, vaccin hexavalent contre diphtérie, tétanos, poliomyélite, coqueluche, infections à Haemophilus influenzae type b, hépatite B Substance active (DCI) vaccin diphtérique, tétanique, coquelucheux (acellulaire, multicomposé), de l'hépatite B (ADNr), poliomyélitique (inactivé) et conjugué de l'Haemophilus de type b (adsorbé) INFECTIOLOGIE - Nouveau médicament Nature de la demande Inscription Avis de la CT du 11 octobre 2017 Pas d’avantage clinique démontré pour la primovaccination et le

2018 Haute Autorite de sante

42. Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza

Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza - ACOG Menu ▼ Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza Page Navigation ▼ Number 753 Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group The Society for Maternal-Fetal Medicine endorses this document. This Committee Opinion was developed by the American College (...) with other organizations, conflict of interest disclosures by representatives of the other organizations are addressed by those organizations. The American College of Obstetricians and Gynecologists has neither solicited nor accepted any commercial involvement in the development of the content of this published product. Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza ABSTRACT: Pregnant and postpartum women are at high risk of serious complications of seasonal and pandemic

2018 American College of Obstetricians and Gynecologists

43. Avian influenza A (H5N1) virus infection

Avian influenza A (H5N1) virus infection Avian influenza A (H5N1) virus infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Avian influenza A (H5N1) virus infection Last reviewed: February 2019 Last updated: September 2018 Summary Notifiable condition. Infection control measures, such as standard, droplet, contact, and airborne precautions, are recommended. High case-fatality rate of approximately 53% among (...) . Definition A contagious disease of animals caused by viruses that infect birds and, less commonly, pigs. Avian influenza A viruses are highly species-specific but have infected other mammals and, on rare occasions, have crossed the species barrier to infect humans. Highly pathogenic avian influenza (HPAI) A H5N1 virus originating in poultry and wild birds can be transmitted to humans, with rare cases of infection transmitted between humans. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person

2018 BMJ Best Practice

44. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. (PubMed)

Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. Baloxavir marboxil is a selective inhibitor of influenza cap-dependent endonuclease. It has shown therapeutic activity in preclinical models of influenza A and B virus infections, including strains resistant to current antiviral agents.We conducted two randomized, double-blind, controlled trials involving otherwise healthy outpatients with acute uncomplicated influenza. After a dose-ranging (10 to 40 mg) placebo (...) -controlled trial, we undertook a placebo- and oseltamivir-controlled trial of single, weight-based doses of baloxavir (40 or 80 mg) in patients 12 to 64 years of age during the 2016-2017 season. The dose of oseltamivir was 75 mg twice daily for 5 days. The primary efficacy end point was the time to alleviation of influenza symptoms in the intention-to-treat infected population.In the phase 2 trial, the median time to alleviation of influenza symptoms was 23.4 to 28.2 hours shorter in the baloxavir groups

2018 NEJM

45. Prevalence of seasonal influenza vaccination among primary healthcare workers in Arar city, Saudi Arabia (PubMed)

Prevalence of seasonal influenza vaccination among primary healthcare workers in Arar city, Saudi Arabia Influenza outbreaks occur annually and have significant ramifications on the wellbeing of the population. Influenza is given high priority in Saudi Arabia where numerous reports of different types of influenza outbreaks have occurred in recent years.The study aimed to determine the prevalence of influenza vaccination among healthcare providers.The study employed a cross-sectional design (...) , and data was collected using a predesigned questionnaire which was validated by a panel of experts and tested for reliability (Cronbach's alpha =0.8). All primary healthcare workers in Arar city (Saudi Arabia) were taken as a comprehensive sample between January and March 2018. The questionnaire used a Likert scale that assessed the reasons for embracing or rejecting the influenza vaccines. A p-value of ≤0.05 was considered statistically significant.In total, 204 health professionals (72 physicians

Full Text available with Trip Pro

2018 Electronic physician

46. Conjugate Haemophilus influenzae type b vaccines for sickle cell disease. (PubMed)

Conjugate Haemophilus influenzae type b vaccines for sickle cell disease. People affected with sickle cell disease (SCD) are at high risk of infection from Haemophilus influenzae type b (Hib). Before the implementation of Haemophilus influenzae type b conjugate vaccination in high-income countries, this was responsible for a high mortality rate in children under five years of age. In African countries, where coverage of this vaccination is still extremely low, Hib remains one of the most common

Full Text available with Trip Pro

2018 Cochrane

47. Influenza

Influenza Top results for influenza - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for influenza The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

48. Influenza vaccine for chronic obstructive pulmonary disease (COPD). (PubMed)

Influenza vaccine for chronic obstructive pulmonary disease (COPD). Influenza vaccinations are currently recommended in the care of people with COPD, but these recommendations are based largely on evidence from observational studies, with very few randomised controlled trials (RCTs) reported. Influenza infection causes excess morbidity and mortality in people with COPD, but there is also the potential for influenza vaccination to cause adverse effects, or not to be cost effective.To determine (...) whether influenza vaccination in people with COPD reduces respiratory illness, reduces mortality, is associated with excess adverse events, and is cost effective.We searched the Cochrane Airways Trials Register, two clinical trials registries, and reference lists of articles. A number of drug companies we contacted also provided references. The latest search was carried out in December 2017.RCTs that compared live or inactivated virus vaccines with placebo, either alone or with another vaccine

2018 Cochrane

49. Influenza Vaccination During Pregnancy

Influenza Vaccination During Pregnancy VOL. 131, NO. 4, APRIL 2018 OBSTETRICS & GYNECOLOGY e109 Influenza Vaccination During Pregnancy ABSTRACT: Influenza vaccination is an essential element of prepregnancy, prenatal, and postpartum care because influenza can result in serious illness, including a higher chance of progressing to pneumonia, when it occurs during the antepartum or postpartum period. In addition to hospitalization, pregnant women with influenza are at increased risk of intensive (...) care unit admission and adverse perinatal and neonatal outcomes. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices and the American College of Obstetricians and Gynecologists recommend that all adults receive an annual influenza vaccine and that women who are or will be pregnant during influenza season receive an inactivated influenza vaccine as soon as it is available. In the United States, the influenza season typically occurs from October to May

2018 American College of Obstetricians and Gynecologists

50. Peramivir (Alpivab) - Influenza, Human

Peramivir (Alpivab) - Influenza, Human 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 22 February 2018 EMA/CHMP/148367/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Alpivab International non (...) Limited submitted on 22 December 2016 an application for marketing authorisation to the European Medicines Agency (EMA) for Alpivab, through the centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 24 September 2015. The applicant applied for the following indication: Treatment of influenza Alpivab is indicated in adults 18 years and older with symptoms typical

2018 European Medicines Agency - EPARs

51. Interventions to increase influenza vaccination rates of those 60 years and older in the community. (PubMed)

Interventions to increase influenza vaccination rates of those 60 years and older in the community. The effectiveness of interventions to increase influenza vaccination uptake in people aged 60 years and older varies by country and participant characteristics. This review updates versions published in 2010 and 2014.To assess access, provider, system, and societal interventions to increase the uptake of influenza vaccination in people aged 60 years and older in the community.We searched CENTRAL (...) , which includes the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE, Embase, CINAHL, and ERIC for this update, as well as WHO ICTRP and ClinicalTrials.gov for ongoing studies to 7 December 2017. We also searched the reference lists of included studies.Randomised controlled trials (RCTs) and cluster-randomised trials of interventions to increase influenza vaccination in people aged 60 years or older in the community.We used standard methodological procedures as specified

2018 Cochrane

52. A trial like ALIC4E: why design a platform, response-adaptive, open, randomised controlled trial of antivirals for influenza-like illness? (PubMed)

A trial like ALIC4E: why design a platform, response-adaptive, open, randomised controlled trial of antivirals for influenza-like illness? ALIC4E is the first publicly funded, multicountry, pragmatic study determining whether antivirals should be routinely prescribed for influenza-like illness in primary care. The trial aims to go beyond determining the average treatment effect in a population to determining effects in patients with combinations of participant characteristics (age, symptom

Full Text available with Trip Pro

2018 ERJ open research

53. Epilepsy in Children After Pandemic Influenza Vaccination

Epilepsy in Children After Pandemic Influenza Vaccination To determine if pandemic influenza vaccination was associated with an increased risk of epilepsy in children.Information from Norwegian registries from 2006 through 2014 on all children <18 years living in Norway on October 1, 2009 was used in Cox regression models to estimate hazard ratios for incident epilepsy after vaccination. A self-controlled case series analysis was used to estimate incidence rate ratios in defined risk periods (...) after pandemic vaccination.In Norway, the main period of the influenza A subtype H1N1 pandemic was from October 2009 to December 2009. On October 1, 2009, 1 154 113 children <18 years of age were registered as residents in Norway. Of these, 572 875 (50.7%) were vaccinated against pandemic influenza. From October 2009 through 2014 there were 3628 new cases of epilepsy (incidence rate 6.09 per 10 000 person-years). The risk of epilepsy was not increased after vaccination: hazard ratio: 1.07; 95

2018 EvidenceUpdates

54. Immunogenicity and safety of subunit influenza vaccines in pregnant women (PubMed)

Immunogenicity and safety of subunit influenza vaccines in pregnant women Pregnancy is a condition of modulated immune suppression, so this group of patients has increased risk of infectious diseases. Trivalent subunit vaccines, unadjusted Agrippal S1 (group I) and immunoadjuvant Grippol Plus (group II), containing 5 μg of actual influenza virus strains, were administered respectively to 37 and 42 women in the second and third trimester of physiological pregnancy. The administration of subunit (...) influenza vaccines was accompanied by the development of local reactions in no more than 10% of patients, compared with 4.9% of the 41 pregnant women in the placebo group (group III). Systemic reactions were of a general somatic nature, did not differ between vaccinated and placebo groups, and were not associated with vaccination. Physiological births in groups I, II and III were 94.6%, 92.9% and 85.4%, respectively, and the birth rates of children without pathologies were 91.9%, 90.5% and 80.5

Full Text available with Trip Pro

2018 ERJ open research

55. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial

Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial To determine whether a 2-week methotrexate (MTX) discontinuation after vaccination improves the efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis (RA).In this prospective randomised parallel-group multicentre study, patients with RA on stable dose of MTX were randomly assigned at a ratio (...) of 1:1 to continue MTX or to hold MTX for 2 weeks after 2016-2017 quadrivalent seasonal influenza vaccine containing H1N1, H3N2, B-Yamagata and B-Victoria. The primary outcome was frequency of satisfactory vaccine response, defined as greater than or equal to fourfold increase of haemagglutination inhibition (HI) antibody titre at 4 weeks after vaccination against ≥2 of four vaccine strains. Secondary endpoints included seroprotection (ie, HI titre ≥1:40) rate, fold change in antibody titres.The

Full Text available with Trip Pro

2018 EvidenceUpdates

56. Influenza epidemiological information prepared for WHO informal meeting on strain composition for inactivated influenza vaccines for use in season 2018-19 Geneva, Feb 2018

Influenza epidemiological information prepared for WHO informal meeting on strain composition for inactivated influenza vaccines for use in season 2018-19 Geneva, Feb 2018 Influenza epidemiological information prepared for WHO informal meeting on strain composition for inactivated influenza vaccines for use in season 2018-19 - NIPH Selected items added to basket Close Search for: Søk Meny Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle Close Health (...) in Norway Close Quality & Knowledge Close Research & Access to data Close About NIPH Close Influenza epidemiological information prepared for WHO informal meeting on strain composition for inactivated influenza vaccines for use in season 2018-19 Have you found an error? Order Download: Key message Summary In February/March, the WHO annually assesses if the components of the influenza vaccine for the northern hemisphere for the coming season should be changed or not. The WHO National Influenza Centre

2018 Norwegian Institute of Public Health

57. Influenza news from the frontline: what's happening? (PubMed)

Influenza news from the frontline: what's happening? Chief Editor Anita Simonds explains what's happening on the frontline of the flu season http://ow.ly/fBW630iiYC5.

Full Text available with Trip Pro

2018 ERJ open research

58. Acute macular neuroretinopathy associated with influenza vaccination with decreased flow at the deep capillary plexus on OCT angiography (PubMed)

Acute macular neuroretinopathy associated with influenza vaccination with decreased flow at the deep capillary plexus on OCT angiography We report a case of acute macular neuroretinopathy (AMN) following routine annual inactivated influenza vaccination. Projection-resolved optical coherence tomography angiography (PR-OCTA) was used to analyze the retinal capillary flow within the AMN lesion.Our patient reported visual symptoms of her right eye nine days after routine annual influenza (...) vaccination. Multimodal imaging revealed small vessel peripheral vasculitis and AMN in the affected eye. Infectious, immunologic, and hypercoagulable etiologies were investigated and excluded. PR-OCTA B-scans within the AMN lesion demonstrated reduced flow in the deep capillary plexus (DCP) at baseline with relatively improved flow signal in the DCP on follow up, 3 weeks later.We report a new association of AMN following routine inactivated influenza immunization. Recent influenza vaccination should

Full Text available with Trip Pro

2018 American journal of ophthalmology case reports

59. The Cost of Interventions to Increase Influenza Vaccination: A Systematic Review

The Cost of Interventions to Increase Influenza Vaccination: A Systematic Review Influenza vaccination rates remain below Healthy People 2020 goals. This project sought to systematically review economic evaluations of healthcare-based quality improvement interventions for improving influenza vaccination uptake among general populations and healthcare workers.The databases MEDLINE, Econlit, Centre for Reviews & Dissemination, Greylit, and Worldcat were searched in July 2016 for papers published (...) from January 2004 to July 2016. Eligible studies evaluated efforts by bodies within the healthcare system to encourage influenza vaccination by means of an organizational or structural change. For each study, program costs per enrollee and per additional enrollee vaccinated were derived (excluding vaccine costs, standardized to 2017 U.S. dollars). Complete economic evaluations were examined when available.Of 2,350 records, 18 articles were eligible and described 29 unique interventions. Most

2018 EvidenceUpdates

60. Vaccines for preventing influenza in healthy children. (PubMed)

Vaccines for preventing influenza in healthy children. The consequences of influenza in children and adults are mainly absenteeism from school and work. However, the risk of complications is greatest in children and people over 65 years of age. This is an update of a review published in 2011. Future updates of this review will be made only when new trials or vaccines become available. Observational data included in previous versions of the review have been retained for historical reasons (...) but have not been updated because of their lack of influence on the review conclusions.To assess the effects (efficacy, effectiveness, and harm) of vaccines against influenza in healthy children.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library 2016, Issue 12), which includes the Cochrane Acute Respiratory Infections Group Specialised Register, MEDLINE (1966 to 31 December 2016), Embase (1974 to 31 December 2016), WHO International Clinical Trials Registry

2018 Cochrane